Pfizer (PFE) Tops Q4 EPS by 8c, Beats on Revenue; Offers FY26 Guidance

Pfizer (NYSE: PFE) reported Q4 EPS of $0.66, $0.08 better than the analyst estimate of $0.58. Revenue for the quarter came in at $17.58 billion versus the consensus estimate of $16.91 billion.

GUIDANCE:

Pfizer sees FY2026 EPS of $2.80-$3.00, versus the consensus of $2.97. Pfizer sees FY2026 revenue of $59.5-62.5 billion, versus the consensus of $61 billion.

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Jefferies cuts China online beauty outlook after July slowdown